

NCC-Bio to Present Strategy to Overcome KRAS Inhibitor Resistance at RAS Summit in Boston

KN510713, the first FAO inhibitor in Phase II oncology trials, shows synergy with KRAS inhibitors and invites co-development partners.

BOSTON, MA, UNITED STATES, September 11, 2025 /EINPresswire.com/ -- [NCC-Bio](#) to Present Breakthrough Strategy for Overcoming KRAS Inhibitor Resistance at the 7th RAS Summit in Boston, September 17



The KRAS inhibitor market is already valued in the billions of dollars. Whoever solves the resistance problem will unlock the true potential of this class!"

*Warren Park, Ph.D. NCC-Bio's
U.S. Partner*

Boston, MA – September 11, 2025 — NCC-Bio, a clinical-stage biotechnology company headquartered in Seoul, Korea, today announced that it will present new clinical and translational findings on its investigational fatty acid oxidation (FAO) inhibitor, [KN510713](#), at the 7th RAS-Targeted Drug Development Summit, taking place September 16–18, 2025, in Boston, Massachusetts. The

presentation by Dr. Soo-Youl Kim, NCC-Bio's CEO and Principal Scientist at the National Cancer Center of Korea, is scheduled for September 17.


The Challenge: Resistance to KRAS Inhibitors

KRAS is the most frequently mutated oncogene in cancer, occurring in approximately 30% of solid tumors such as pancreatic, lung, and colorectal cancers. While the approval of the first KRAS G12C inhibitors — sotorasib (Amgen) and adagrasib (BMS/Mirati) — has transformed treatment options for subsets of patients, these therapies are hindered by rapid emergence of resistance.


NCC-Bio's research has identified the underlying cause of this resistance. Inhibition of KRAS triggers autophagy and lipophagy, leading to enhanced fatty acid oxidation (FAO), which fuels cancer cell survival despite targeted therapy.

The Solution: Targeting FAO with KN510713

KN510713 is designed to block this escape mechanism. By inhibiting FAO in combination with KRAS inhibitors, cancer cells are unable to generate the ATP needed for survival. This dual



Emerging Cancer Therapeutic Approach to Overcome Challenges of Targeted Therapeutics & Treat RAS-Driven Cancers




Soo-Youl Kim

Research Institute, National Cancer Center, New Cancer Cure-Bio Co., Republic of Korea


Summary
 Combining soritasorb with an FAO inhibitor (KN510713) has triggered a powerful wave of cancer cell death. This novel combination strategy clearly proves that treating KRAS-mutant lung and pancreatic cancer patients with this approach, alongside first-line chemotherapy, effectively overcomes acquired resistance.

Proposal / Discovery


Stopping Acquired Resistance



POC Confirmed



Opportunity / KN510713



CAC: catalase acyl carnitine oxidase; KNS3 target
 ACAD: acyl-CoA dehydrogenation; LC3-II target
 mTORC1: mammalian target of rapamycin complex 1; mTORC1 target
 mTORC2: mammalian target of rapamycin complex 2; mTORC2 target
 AMPK: adenosine monophosphate kinase; AMPK target
 GSK-3β: glycogen synthase kinase-3β; GSK-3β target
 AKT: protein kinase B; AKT target
 ERK: extracellular signal-regulated kinase; ERK target
 JNK: c-Jun N-terminal kinase; JNK target
 p38: p38 mitogen-activated protein kinase; p38 target
 IKK: IκB kinase; IKK target
 NF-κB: nuclear factor-kappa B; NF-κB target
 FOXO: forkhead box O; FOXO target
 SIRT6: sirtuin 6; SIRT6 target
 HDAC: histone deacetylase; HDAC target
 DNMT: DNA methyltransferase; DNMT target
 TET: ten-eleven translocation; TET target
 UHRF1: ubiquitin-protein ligase E3 component 1; UHRF1 target
 BRCA1: breast cancer type 1 susceptibility protein; BRCA1 target
 BRCA2: breast cancer type 2 susceptibility protein; BRCA2 target
 PALM: poly(ADP-ribose) polymerase; PALM target
 ATRX: ataxin ring finger 1; ATRX target
 DNMT3A: DNA methyltransferase 3A; DNMT3A target
 DNMT3B: DNA methyltransferase 3B; DNMT3B target
 DNMT3L: DNA methyltransferase 3-like; DNMT3L target
 DNMT3H: DNA methyltransferase 3H; DNMT3H target
 DNMT3J: DNA methyltransferase 3J; DNMT3J target
 DNMT3K: DNA methyltransferase 3K; DNMT3K target
 DNMT3G: DNA methyltransferase 3G; DNMT3G target
 DNMT3I: DNA methyltransferase 3I; DNMT3I target
 DNMT3M: DNA methyltransferase 3M; DNMT3M target
 DNMT3N: DNA methyltransferase 3N; DNMT3N target
 DNMT3O: DNA methyltransferase 3O; DNMT3O target
 DNMT3P: DNA methyltransferase 3P; DNMT3P target
 DNMT3Q: DNA methyltransferase 3Q; DNMT3Q target
 DNMT3R: DNA methyltransferase 3R; DNMT3R target
 DNMT3S: DNA methyltransferase 3S; DNMT3S target
 DNMT3T: DNA methyltransferase 3T; DNMT3T target
 DNMT3U: DNA methyltransferase 3U; DNMT3U target
 DNMT3V: DNA methyltransferase 3V; DNMT3V target
 DNMT3W: DNA methyltransferase 3W; DNMT3W target
 DNMT3X: DNA methyltransferase 3X; DNMT3X target
 DNMT3Y: DNA methyltransferase 3Y; DNMT3Y target
 DNMT3Z: DNA methyltransferase 3Z; DNMT3Z target
 DNMT3AA: DNA methyltransferase 3AA; DNMT3AA target
 DNMT3AB: DNA methyltransferase 3AB; DNMT3AB target
 DNMT3AC: DNA methyltransferase 3AC; DNMT3AC target
 DNMT3AD: DNA methyltransferase 3AD; DNMT3AD target
 DNMT3AE: DNA methyltransferase 3AE; DNMT3AE target
 DNMT3AF: DNA methyltransferase 3AF; DNMT3AF target
 DNMT3AG: DNA methyltransferase 3AG; DNMT3AG target
 DNMT3AH: DNA methyltransferase 3AH; DNMT3AH target
 DNMT3AI: DNA methyltransferase 3AI; DNMT3AI target
 DNMT3AJ: DNA methyltransferase 3AJ; DNMT3AJ target
 DNMT3AK: DNA methyltransferase 3AK; DNMT3AK target
 DNMT3AL: DNA methyltransferase 3AL; DNMT3AL target
 DNMT3AM: DNA methyltransferase 3AM; DNMT3AM target
 DNMT3AN: DNA methyltransferase 3AN; DNMT3AN target
 DNMT3AO: DNA methyltransferase 3AO; DNMT3AO target
 DNMT3AP: DNA methyltransferase 3AP; DNMT3AP target
 DNMT3AQ: DNA methyltransferase 3AQ; DNMT3AQ target
 DNMT3AR: DNA methyltransferase 3AR; DNMT3AR target
 DNMT3AS: DNA methyltransferase 3AS; DNMT3AS target
 DNMT3AT: DNA methyltransferase 3AT; DNMT3AT target
 DNMT3AU: DNA methyltransferase 3AU; DNMT3AU target
 DNMT3AV: DNA methyltransferase 3AV; DNMT3AV target
 DNMT3AW: DNA methyltransferase 3AW; DNMT3AW target
 DNMT3AX: DNA methyltransferase 3AX; DNMT3AX target
 DNMT3AY: DNA methyltransferase 3AY; DNMT3AY target
 DNMT3AZ: DNA methyltransferase 3AZ; DNMT3AZ target
 DNMT3BA: DNA methyltransferase 3BA; DNMT3BA target
 DNMT3BB: DNA methyltransferase 3BB; DNMT3BB target
 DNMT3BC: DNA methyltransferase 3BC; DNMT3BC target
 DNMT3BD: DNA methyltransferase 3BD; DNMT3BD target
 DNMT3BE: DNA methyltransferase 3BE; DNMT3BE target
 DNMT3BF: DNA methyltransferase 3BF; DNMT3BF target
 DNMT3BG: DNA methyltransferase 3BG; DNMT3BG target
 DNMT3BH: DNA methyltransferase 3BH; DNMT3BH target
 DNMT3BI: DNA methyltransferase 3BI; DNMT3BI target
 DNMT3BJ: DNA methyltransferase 3BJ; DNMT3BJ target
 DNMT3BK: DNA methyltransferase 3BK; DNMT3BK target
 DNMT3BL: DNA methyltransferase 3BL; DNMT3BL target
 DNMT3BM: DNA methyltransferase 3BM; DNMT3BM target
 DNMT3BN: DNA methyltransferase 3BN; DNMT3BN target
 DNMT3BO: DNA methyltransferase 3BO; DNMT3BO target
 DNMT3BP: DNA methyltransferase 3BP; DNMT3BP target
 DNMT3BQ: DNA methyltransferase 3BQ; DNMT3BQ target
 DNMT3BR: DNA methyltransferase 3BR; DNMT3BR target
 DNMT3BS: DNA methyltransferase 3BS; DNMT3BS target
 DNMT3BT: DNA methyltransferase 3BT; DNMT3BT target
 DNMT3BU: DNA methyltransferase 3BU; DNMT3BU target
 DNMT3BV: DNA methyltransferase 3BV; DNMT3BV target
 DNMT3BW: DNA methyltransferase 3BW; DNMT3BW target
 DNMT3BX: DNA methyltransferase 3BX; DNMT3BX target
 DNMT3BY: DNA methyltransferase 3BY; DNMT3BY target
 DNMT3BZ: DNA methyltransferase 3BZ; DNMT3BZ target
 DNMT3CA: DNA methyltransferase 3CA; DNMT3CA target
 DNMT3CB: DNA methyltransferase 3CB; DNMT3CB target
 DNMT3CC: DNA methyltransferase 3CC; DNMT3CC target
 DNMT3CD: DNA methyltransferase 3CD; DNMT3CD target
 DNMT3CE: DNA methyltransferase 3CE; DNMT3CE target
 DNMT3CF: DNA methyltransferase 3CF; DNMT3CF target
 DNMT3CG: DNA methyltransferase 3CG; DNMT3CG target
 DNMT3CH: DNA methyltransferase 3CH; DNMT3CH target
 DNMT3CI: DNA methyltransferase 3CI; DNMT3CI target
 DNMT3CJ: DNA methyltransferase 3CJ; DNMT3CJ target
 DNMT3CK: DNA methyltransferase 3CK; DNMT3CK target
 DNMT3CL: DNA methyltransferase 3CL; DNMT3CL target
 DNMT3CM: DNA methyltransferase 3CM; DNMT3CM target
 DNMT3CN: DNA methyltransferase 3CN; DNMT3CN target
 DNMT3CO: DNA methyltransferase 3CO; DNMT3CO target
 DNMT3CP: DNA methyltransferase 3CP; DNMT3CP target
 DNMT3CQ: DNA methyltransferase 3CQ; DNMT3CQ target
 DNMT3CR: DNA methyltransferase 3CR; DNMT3CR target
 DNMT3CS: DNA methyltransferase 3CS; DNMT3CS target
 DNMT3CT: DNA methyltransferase 3CT; DNMT3CT target
 DNMT3CU: DNA methyltransferase 3CU; DNMT3CU target
 DNMT3CV: DNA methyltransferase 3CV; DNMT3CV target
 DNMT3CW: DNA methyltransferase 3CW; DNMT3CW target
 DNMT3CX: DNA methyltransferase 3CX; DNMT3CX target
 DNMT3CY: DNA methyltransferase 3CY; DNMT3CY target
 DNMT3CZ: DNA methyltransferase 3CZ; DNMT3CZ target
 DNMT3DA: DNA methyltransferase 3DA; DNMT3DA target
 DNMT3DB: DNA methyltransferase 3DB; DNMT3DB target
 DNMT3DC: DNA methyltransferase 3DC; DNMT3DC target
 DNMT3DD: DNA methyltransferase 3DD; DNMT3DD target
 DNMT3DE: DNA methyltransferase 3DE; DNMT3DE target
 DNMT3DF: DNA methyltransferase 3DF; DNMT3DF target
 DNMT3DG: DNA methyltransferase 3DG; DNMT3DG target
 DNMT3DH: DNA methyltransferase 3DH; DNMT3DH target
 DNMT3DI: DNA methyltransferase 3DI; DNMT3DI target
 DNMT3DJ: DNA methyltransferase 3DJ; DNMT3DJ target
 DNMT3DK: DNA methyltransferase 3DK; DNMT3DK target
 DNMT3DL: DNA methyltransferase 3DL; DNMT3DL target
 DNMT3DM: DNA methyltransferase 3DM; DNMT3DM target
 DNMT3DN: DNA methyltransferase 3DN; DNMT3DN target
 DNMT3DO: DNA methyltransferase 3DO; DNMT3DO target
 DNMT3DP: DNA methyltransferase 3DP; DNMT3DP target
 DNMT3DQ: DNA methyltransferase 3DQ; DNMT3DQ target
 DNMT3DR: DNA methyltransferase 3DR; DNMT3DR target
 DNMT3DS: DNA methyltransferase 3DS; DNMT3DS target
 DNMT3DT: DNA methyltransferase 3DT; DNMT3DT target
 DNMT3DU: DNA methyltransferase 3DU; DNMT3DU target
 DNMT3DV: DNA methyltransferase 3DV; DNMT3DV target
 DNMT3DW: DNA methyltransferase 3DW; DNMT3DW target
 DNMT3DX: DNA methyltransferase 3DX; DNMT3DX target
 DNMT3DY: DNA methyltransferase 3DY; DNMT3DY target
 DNMT3DZ: DNA methyltransferase 3DZ; DNMT3DZ target
 DNMT3EA: DNA methyltransferase 3EA; DNMT3EA target
 DNMT3EB: DNA methyltransferase 3EB; DNMT3EB target
 DNMT3EC: DNA methyltransferase 3EC; DNMT3EC target
 DNMT3ED: DNA methyltransferase 3ED; DNMT3ED target
 DNMT3EE: DNA methyltransferase 3EE; DNMT3EE target
 DNMT3EF: DNA methyltransferase 3EF; DNMT3EF target
 DNMT3EG: DNA methyltransferase 3EG; DNMT3EG target
 DNMT3EH: DNA methyltransferase 3EH; DNMT3EH target
 DNMT3EI: DNA methyltransferase 3EI; DNMT3EI target
 DNMT3EJ: DNA methyltransferase 3EJ; DNMT3EJ target
 DN

Presenter: Dr. Soo-Youl Kim, CEO of NCC-Bio
Date/Time: September 17, 2025
Event: 7th RAS-Targeted Drug Development Summit
Location: Boston, Massachusetts

About NCC-Bio

NCC-Bio is a clinical-stage biotechnology company developing innovative therapies targeting cancer energy metabolism. Its lead program, KN510713, is the first fatty acid oxidation (FAO) inhibitor to enter oncology clinical trials worldwide. NCC-Bio is headquartered in Seoul, Korea, with plans to expand operations in the United States to support Phase II studies and global partnerships.

For more information, please visit www.nccbio.co.kr.

About GR Boston North (Global Bio Match Service)

GR Boston North is an executive search and biotech business development platform connecting innovative life science companies with investors, partners, and senior leadership talent. As NCC-Bio's U.S. business development partner, GR Boston North supports strategic collaborations and fundraising for the KN510713 program.

Media & Investor Contact

Warren Park, Ph.D.

CEO, GRN Boston North

Email: wpark@grnbostonnorth.com

Scientific Contact

Dr. Soo-Youl Kim

CEO, NCC-Bio | Principal Scientist, National Cancer Center, Korea

Email: kimsooyoul@gmail.com

Warren Park

GR Boston North

+1 978-269-4198

wpark@grnbostonnorth.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/847172830>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.